新药物时代下NSCLC脑转移瘤治疗策略的改变

Advanced treatment strategies for NSCLC brain metastasis in the new drug era

非小细胞肺癌(NSCLC)脑转移患者的预后极差.目前,局部放疗仍然是NSCLC脑转移的标准治疗选择.此外,酪氨酸激酶抑制剂(TKI)为驱动基因阳性NSCLC脑转移患者带来了福音,其中抗血管生成药物在NSCLC脑转移的治疗中主要发挥伴侣作用,与放疗、化疗、分子靶向治疗联合应用的疗效及安全性已有较多探索,而免疫检测点抑制剂(ICIs)在NSCLC脑转移患者尤其是驱动基因阴性患者中发挥怎样的作用,已经成为研究者关注的焦点.本文将综述新药物时代下NSCLC脑转移瘤治疗策略的改变,分析现有研究的局限和未来面临的挑战.

Non-small cell lung cancer(NSCLC)patients with brain metastasis present extremely poor prognosis.At present,local radiotherapy is still the standard treatment option for NSCLC with brain metastasis.In addition,tyrosine kinase inhibitor(TKI)brings new option for driver gene-positive NSCLC patients with brain metastasis,in which the anti-angiogenic drugs play a companionate role in the treatment of NSCLC with brain metastasis.AThere are further investigations for exploring the efficacy and safety of its combination application with radiotherapy,chemotherapy and molecular targeted therapy.The role of immune checkpoint inhibitors(ICIs)in NSCLC patients with brain metastasis,especially in driving gene-negative patients,has been attracted the researchers.In this article,wereview the progress on the therapeutic strategies for NSCLC with brain metastasis in the new drug era,and analyze the limitations of existing research and the facing challenges in the future.